Cathelicidin (hCAP-18 / Synthetic Derivatives) vs LL-37 — Peptide Comparison

Cathelicidin (hCAP-18 / Synthetic Derivatives) vs LL-37 — Peptide Comparison Cathelicidin (hCAP-18 / Synthetic Derivatives) vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is… At a Glance Dose Range Cathelicidin (hCAP-18 / Synthetic Derivatives) 0.5–5 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Once daily Administration Topical application (primary research route) Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Antibiotic-Resistant Infections Biofilm Destruction Immune System Support Wound Healing Fighting Infections Immune Boost Technical Data Molecular Formula hCAP-18: ~18 kDa precursor protein (170 AA); SAAP-148: C155H253N49O31 (approximate), MW 3,267.1 Da Molecular Weight hCAP-18 precursor: ~18,000 Da; SAAP-148: 3,267.1 Da; OP-145: ~2,900 Da Half-Life Plasma half-life: minutes (proteolytic degradation); local tissue persistence: hours at therapeutic concentrations in wound environment; enhanced stability compared to LL-37 due to N-terminal acetylation and C-terminal amidation Bioavailability Topical bioavailability optimized in hypromellose ointment formulations; SAAP-148 retains activity in human plasma unlike LL-37; systemic bioavailability limited by proteolytic degradation CAS Number Not assigned (SAAP-148 and OP-145 are novel synthetic derivatives) C205H340N60O53 4,493.26 Da Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery 154947-66-7 Protocols standard 0.5 mg/mL drops (about 100 microliters per application) Twice daily 2 weeks In a human phase 2a ear study, OP-145 drops at 0.5 mg per mL were applied to the affected ear twice daily for 2 weeks and were safe and well tolerated [4]. starting 0.5 mg/mL gel Twice weekly 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. Applications Research into next-generation antimicrobials against multidrug-resistant infections Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on research into next-generation antimicrobials against multidrug-resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Topical antimicrobial development for wound infections with biofilm involvement Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on topical antimicrobial development for wound infections with biofilm involvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Understanding vitamin D-cathelicidin innate immune axis for immune optimization Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on understanding vitamin d-cathelicidin innate immune axis for immune optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Development of anti-biofilm therapeutics for chronic device-related and wound infections Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on development of anti-biofilm therapeutics for chronic device-related and wound infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area whe Common Local application site irritation Local inflammatory response Mild wound exudate increase Uncommon Localized urticaria Transient pain at injection site Serious Hemolytic activity at supratherapeutic doses Local site irritation Transient stinging or burning Mild perilesional erythema Increased wound exudate Allergic contact reaction Hemolytic activity at systemic concentrations Research Status FDA Status Research compound Safety Overview Cathelicidin peptides (natural and synthetic) are not FDA-approved and have no completed human clinical trials. Animal studies demonstrate broad-spectrum antimicrobial activity without systemic toxicity at therapeutic concentrations. However, concern exists regarding immunological tolerance—cathelicidin derivatives can trigger innate immune activation and inflammatory responses at high concentrations. The peptide's mechanism on immune cells is incompletely understood in humans, and effects on chronic immune signaling, tolerance development, or off-target immune activation remain uncharacterized. Bacterial resistance development to cathelicidin-based therapeutics is theoretically possible but not yet documented clinically. Contraindications xKnown hypersensitivity to cathelicidin-derived peptides or formulation components xPregnancy and breastfeeding — insufficient reproductive safety data for synthetic derivatives xActive autoimmune conditions involving cathelicidin dysregulation (e.g., rosacea, psoriasis) — exogenous cathelicidin peptides may exacerbate inflammation xSevere systemic immunodeficiency without medical supervision — immune modulation effects may be unpredictable LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered Decision Guide Choose Cathelicidin (hCAP-18 / Synthetic Derivatives) if... Research into next-generation antimicrobials against multidrug-resistant infections Topical antimicrobial development for wound infections with biofilm involvement Understanding vitamin D-cathelicidin innate immune axis for immune optimization Development of anti-biofilm therapeutics for chronic device-related and wound infections Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals